Literature DB >> 23232912

Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India.

Abhijit Chakraborty1, Ashis Mukhopadhyay, Deboshree Bhattacharyya, Chinmoy Kr Bose, Keya Choudhuri, Soma Mukhopadhyay, Jayasri Basak.   

Abstract

The incidence of breast cancer in India is on the rise and is rapidly becoming the number one cancer in females pushing the cervical cancer to the second position. The mutations in two breast cancer susceptibility genes, BRCA1 and BRCA2, are frequently associated with familial breast cancer. The main objective of the study was to determine the frequency of the mutation 5382insC in BRCA1 of eastern Indian breast cancer patients and also study the hormonal receptor status and histopathology of the patients. Altogether 92 patients affected with breast cancer were included in this study. ARMS-PCR based amplification was used to detect the presence of mutation. The mutations were considered only after pedigree analysis. Out of 92 patients (age range: 20-77 years) with family history (57 individuals) and without family history (35 individuals) were screened. Fifty controls have been systematically investigated. Seven patients and two family members were found to be carriers of 5382insC mutation in BRCA1 gene. We have found 42.64 % ER(-)/PR(-) cancer and 20.58 % triple negative cancer. Invasive ductal carcinoma is the most common histology among the investigated individuals. The presented data confirm a noticeable contribution of BRCA1 5382insC mutation in BC development in Eastern India, which may justify an extended BRCA1 5382insC testing within this patient population. We found HER-2/neu negativity and BRCA1 positivity associated with familial breast cancer. From the hospital's patient history, it was revealed that the age of menarche plays an important role in development of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23232912     DOI: 10.1007/s10689-012-9590-y

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  38 in total

1.  Simple and rapid detection of BRCA1 and BRCA2 mutations by multiplex mutagenically separated PCR.

Authors:  P C Chan; B Y Wong; H Ozcelik; D E Cole
Journal:  Clin Chem       Date:  1999-08       Impact factor: 8.327

2.  Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families.

Authors:  B Newman; M A Austin; M Lee; M C King
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

3.  Cost-effective mammography screening in Korea: high incidence of breast cancer in young women.

Authors:  Soon Young Lee; Seong Hwa Jeong; Youn Nam Kim; Jinheum Kim; Dae Ryong Kang; Hyeon-Chang Kim; Chung Mo Nam
Journal:  Cancer Sci       Date:  2009-03-02       Impact factor: 6.716

4.  Risk factors for breast cancer according to age at diagnosis in a French case-control study.

Authors:  C Bouchardy; M G Lê; C Hill
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

5.  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Authors:  S Håkansson; O Johannsson; U Johansson; G Sellberg; N Loman; A M Gerdes; E Holmberg; N Dahl; N Pandis; U Kristoffersson; H Olsson; A Borg
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

6.  Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.

Authors:  S A Gayther; J Mangion; P Russell; S Seal; R Barfoot; B A Ponder; M R Stratton; D Easton
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

7.  Induced abortion and the risk of breast cancer.

Authors:  M Melbye; J Wohlfahrt; J H Olsen; M Frisch; T Westergaard; K Helweg-Larsen; P K Andersen
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

8.  Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.

Authors:  P Vehmanen; L S Friedman; H Eerola; M McClure; B Ward; L Sarantaus; T Kainu; K Syrjäkoski; S Pyrhönen; O P Kallioniemi; T Muhonen; M Luce; T S Frank; H Nevanlinna
Journal:  Hum Mol Genet       Date:  1997-12       Impact factor: 6.150

9.  A case-control study of breast cancer in Tianjin, China.

Authors:  Q S Wang; R K Ross; M C Yu; J P Ning; B E Henderson; H T Kimm
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1992 Sep-Oct       Impact factor: 4.254

10.  Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.

Authors:  Sunita Saxena; Anurupa Chakraborty; Mishi Kaushal; Sanjeev Kotwal; Dinesh Bhatanager; Ravindar S Mohil; Chintamani Chintamani; Anil K Aggarwal; Veena K Sharma; Prakash C Sharma; Gilbert Lenoir; David E Goldgar; Csilla I Szabo
Journal:  BMC Med Genet       Date:  2006-10-04       Impact factor: 2.103

View more
  3 in total

Review 1.  Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India.

Authors:  Archana Sharma-Oates; Abeer M Shaaban; Ian Tomlinson; Luke Wynne; Jean-Baptiste Cazier; Sudha Sundar
Journal:  Precis Clin Med       Date:  2018-09-22

2.  Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.

Authors:  Rumyana Ivanova Dodova; Atanaska Velichkova Mitkova; Daniela Rosenova Dacheva; Lina Basam Hadjo; Alexandrina Ivanova Vlahova; Margarita Stoyanova Taushanova -Hadjieva; Spartak Stoyanov Valev; Marija Mitko Caulevska; Stanislava Dimitrova Popova; Ivan Emilov Popov; Tihomir Iliichev Dikov; Theophil Angelov Sedloev; Atanas Stefanov Ionkov; Konstanta Velinova Timcheva; Svetlana Liubomirova Christova; Ivo Marinov Kremensky; Vanio Ivanov Mitev; Radka Petrova Kaneva
Journal:  BMC Cancer       Date:  2015-07-17       Impact factor: 4.430

Review 3.  A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Authors:  Fatemeh Karami; Parvin Mehdipour
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.